Effects of policosanol on serum lipids and heme oxygenase-1 in patients with hyperlipidemia
10.3760/cma.j.issn.0253-3758.2012.10.008
- VernacularTitle:多廿烷醇对高脂血症患者血脂谱和血红素氧合酶1的作用
- Author:
Shun LIU
1
;
Ming-Yue TAN
;
Shui-Ping ZHAO
;
Hui RONG
Author Information
1. 中南大学湘雅二医院心内科
- Keywords:
Hyperlipidemia;
Heme oxygenase(decyclizing);
Policosanol
- From:
Chinese Journal of Cardiology
2012;40(10):840-843
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of policosanol on serum lipid and heme oxygenase-1 (HO-1) in patients with byperlipidemia.Methods This randomized,open study included 72 patients with hyperlipidemia.The patients were randomly assigned to treatment group (policosanol,20 mg/d,n =36) or placebo group (placebo,two tablets/d,n =36).The levels of serum lipids,hypersensitive C-reactive protein (hs-CRP),HO-1 were assessed before and after 16 weeks treatment.Drug-induced adverse effects and events were recorded during the observation period.The serum HO-1 was measured by ELISA.Results (1) After 16 weeks,all parameters remained unchanged in the placebo group; the level of TC decreased from (7.01 ± 1.03)mmol/L to (5.66 ±0.83)mmol/L(-19.4％,P ＜0.01),the level of LDL-C decreased from (4.78 ± 0.72) mmol/L to (3.70 ± 0.69) mmol/L(-22.5％,P ＜ 0.01) in the treatment group.TG and HDL-C levels remained unchanged (P ＞ 0.05) while the level of HO-1 significantly decreased from (1.82 ± 1.08) μg/L to (1.45 ±0.81) μg/L (P ＜0.01) and the level of hs-CRP decreased from (3.40 ± 3.64) mg/L to (1.86 ± 2.02) mg/L (P ＜ 0.01) in the treatment group.(2) Safety index was similar between placebo and treatment groups (P ＞ 0.05) and there was no adverse events including allergic reaction,muscle pain in all subjects during the observation period.Conclusion The short-term data obtained from this small hyperlipidemia patient cohort suggest that policosanol is a safe lipid-lowering and anti-inflammatory agent for hyperlipidemia patients.
